Serum osteocalcin concentration in horses treated with triamcinolone acetonide.

The research investigates the effect of triamcinolone acetonide on the serum osteocalcin concentration in horses, revealing a significant decrease post-treatment in both healthy horses and ones with chronic obstructive pulmonary disease, with most horses returning to pre-treatment levels within 28 days.

Study Overview

• The purpose of the study was to examine the impact of triamcinolone acetonide, a synthetic corticosteroid, on the serum concentration of osteocalcin, a protein that plays a vital role in bone mineralization in horses.

Research Design

• To conduct the research, the scientists formed two groups of horses—a group of five clinically normal horses (Group 1) and a group of five horses suffering from chronic obstructive pulmonary disease (Group 2).
• Both groups were treated with 0.09 mg/kg of body weight of triamcinolone acetonide (via intramuscular injection).

Pretreatment Observations

• Prior to the treatment, the researchers performed a t-test to identify whether there was a significant difference in serum osteocalcin concentration between the two groups. The results indicated no significant variation.

Post-treatment Observations

• Following treatment, a noticeable decrease in serum osteocalcin concentration was observed in both groups. This reduction was statistically significant as validated by a P-value of less than 0.05.
• The minimum osteocalcin concentration in individual horses was recorded 24 to 48 hours after the treatment.
• The researchers noted that the response of serum osteocalcin to glucocorticoid administration was similar in both groups.

Recovery Observations

• Most horses (7 out of 10) returned to pretreatment concentrations of serum osteocalcin after 28 days of the original treatment.
• The rest of the horses (3 out of 10) reached pretreatment values between 62 and 150 days after the treatment.